Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community-Based Treatment Efficacy of Harvoni in Chronic Hepatitis C
NCT02339038Phase 4Completed
- Sponsor
- National Institutes of Health
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Harvoni in hepatitis C (HCV), sponsored by National Institutes of Health. Primary endpoint: Sustained Viral Response 12 Weeks After Treatment. Started Jan 2015; status: completed.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02339038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339038.